JNJJanssen Research & Development, LLCSigning up patients
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,000 (planned)
- Started
- Sep 9, 2026
- Main results expected
- Sep 4, 2030
- Fully finished
- Feb 2, 2035
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Up to approximately 62 months
Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR)
Measured over: Up to 12 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07665450 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC